Carvedilol
- Generic Name
- Carvedilol
- Brand Names
- Coreg
- Drug Type
- Small Molecule
- Chemical Formula
- C24H26N2O4
- CAS Number
- 72956-09-3
- Unique Ingredient Identifier
- 0K47UL67F2
- Background
Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker. It is currently used to treat heart failure, left ventricular dysfunction, and hypertension. The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs ...
- Indication
Carvedilol is indicated to treat mild to severe heart failure, left ventricular dysfunction after myocardial infarction with ventricular ejection fraction ≤40%, or hypertension.
- Associated Conditions
- Atrial Fibrillation, Chronic Stable Angina Pectoris, Hypertension, LVEF ≤40% Left ventricular dysfunction, NYHA Class I or II heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV)
- Associated Therapies
- -
Pharmacological Reduction of Right Ventricular Enlargement
- Conditions
- Interventions
- First Posted Date
- 2020-04-14
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 180
- Registration Number
- NCT04345796
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
HVPG-Guided Therapy vs Carvedilol Plus Endotherapy for the Prevention of Esophageal Variceal Rebleeding in Cirrhotic Patients
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Air Force Military Medical University, China
- Target Recruit Count
- 220
- Registration Number
- NCT04254822
- Locations
- 🇨🇳
Fourth Military Medical University, Xi'an, Shaanxi, China
Cardiac Changes in Early Parkinson's Disease: a Follow Up Study
- Conditions
- Interventions
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT04218968
- Locations
- 🇺🇸
Michele L Lima Gregorio, Los Angeles, California, United States
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
- Conditions
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT04190433
Mechanism of Masked Hypertension - Intervention
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- University of Alabama at Birmingham
- Registration Number
- NCT04121299
- Locations
- 🇺🇸
Hypertension Research Clinic at UAB, Birmingham, Alabama, United States
Risk-Guided Cardioprotection with Carvedilol in Breast Cancer Patients Treated with Doxorubicin And/or Trastuzumab
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 69
- Registration Number
- NCT04023110
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2021-04-12
- Lead Sponsor
- West Virginia University
- Registration Number
- NCT03980249
- Locations
- 🇺🇸
WVU Cancer Institute - Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 450
- Registration Number
- NCT03879629
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Comparison of Carvedilol and Atorvastatin for Preventing of Contrast-Induced Nephropathy.
- Conditions
- Interventions
- First Posted Date
- 2019-03-08
- Last Posted Date
- 2019-03-12
- Lead Sponsor
- rabab ahmed mohamed
- Target Recruit Count
- 144
- Registration Number
- NCT03867994
Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells
- First Posted Date
- 2019-03-04
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- West Virginia University
- Target Recruit Count
- 4
- Registration Number
- NCT03861598
- Locations
- 🇺🇸
WVU Cancer Institute - Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.